Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
AstraZeneca
Colorcon
Johnson and Johnson
Baxter

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Foscarnet sodium - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for foscarnet sodium and what is the scope of patent protection?

Foscarnet sodium is the generic ingredient in two branded drugs marketed by Hospira and Clinigen Hlthcare, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for foscarnet sodium. One supplier is listed for this compound.

Summary for foscarnet sodium
Recent Clinical Trials for foscarnet sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
CttqPhase 4
Peking University People's HospitalPhase 4
National Cancer Institute (NCI)N/A

See all foscarnet sodium clinical trials

Pharmacology for foscarnet sodium
Medical Subject Heading (MeSH) Categories for foscarnet sodium

US Patents and Regulatory Information for foscarnet sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Clinigen Hlthcare FOSCAVIR foscarnet sodium INJECTABLE;INJECTION 020068-001 Sep 27, 1991 RX Yes Yes   Start Trial   Start Trial   Start Trial
Hospira FOSCARNET SODIUM foscarnet sodium INJECTABLE;INJECTION 077174-001 May 31, 2005 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for foscarnet sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Clinigen Hlthcare FOSCAVIR foscarnet sodium INJECTABLE;INJECTION 020068-001 Sep 27, 1991   Start Trial   Start Trial
Clinigen Hlthcare FOSCAVIR foscarnet sodium INJECTABLE;INJECTION 020068-001 Sep 27, 1991   Start Trial   Start Trial
Clinigen Hlthcare FOSCAVIR foscarnet sodium INJECTABLE;INJECTION 020068-001 Sep 27, 1991   Start Trial   Start Trial
Clinigen Hlthcare FOSCAVIR foscarnet sodium INJECTABLE;INJECTION 020068-001 Sep 27, 1991   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Medtronic
AstraZeneca
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.